Over the past year there were no insider purchases at Esperion Therapeutics, Inc.. Three insiders sold roughly $579,000 instead.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Looker Benjamin | Executive Officer | Sell | 11,824 | $3.16 | $37K | SEC |
| Jun 18, 2026 | Koenig Sheldon L. | CEO | Sell | 53,588 | $3.16 | $169K | SEC |
| Jun 18, 2026 | Halladay Benjamin | CFO | Sell | 10,773 | $3.16 | $34K | SEC |
| Mar 18, 2026 | Looker Benjamin | Executive Officer | Sell | 5,708 | $2.70 | $15K | SEC |
| Mar 18, 2026 | Koenig Sheldon L. | CEO | Sell | 25,578 | $2.72 | $70K | SEC |
| Mar 18, 2026 | Halladay Benjamin | CFO | Sell | 6,424 | $2.71 | $17K | SEC |
| Jan 21, 2026 | Looker Benjamin | Executive Officer | Sell | 1,689 | $2.88 | $5K | SEC |
| Dec 18, 2025 | Koenig Sheldon L. | CEO | Sell | 48,244 | $3.67 | $177K | SEC |
| Dec 18, 2025 | Halladay Benjamin | CFO | Sell | 7,337 | $3.67 | $27K | SEC |
| Dec 18, 2025 | Looker Benjamin | Executive Officer | Sell | 6,517 | $3.67 | $24K | SEC |
| Oct 20, 2025 | Looker Benjamin | Executive Officer | Sell | 1,248 | $2.62 | $3K | SEC |
| Sep 18, 2025 | Looker Benjamin | Executive Officer | Sell | 6,267 | $2.80 | $18K | SEC |
| Sep 18, 2025 | Koenig Sheldon L. | CEO | Sell | 28,427 | $2.79 | $79K | SEC |
| Sep 18, 2025 | Halladay Benjamin | CFO | Sell | 7,046 | $2.81 | $20K | SEC |
| Jul 18, 2025 | Halladay Benjamin | CFO | Sell | 11 | $1.12 | $12 | SEC |
In the last 12 months Esperion Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $579,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ESPR was filed on 2026-06-18.
No congressional trades in ESPR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).